Venture Capital Funding Survey, First Quarter 2015
VENTURE CAPITAL FUNDING, FIRST QUARTER 2015 This is a listing of many of the Bay Area firms that received venture capital financing between Jan. 1 and Mar. 31, 2015. Most of the data was compiled from a survey conducted by PricewaterhouseCoopers, Thomson Venture Economics and the National Venture Capital Association in conjunction with the Mercury News. In the case of some investments there may have been other participants in the round who are not credited. Also, the amounts listed may not include all venture funding the company received during the quarter. *Indicates this is a seed or first-round infusion of money from venture capitalists. These companies may have received money previously from other investors and aren't necessarily startups. BIOTECHNOLOGY / HEALTH Name
10X Genomics*
Balance Therapeutics*
Caribou Biosciences*
Diacarta*
Lifecode*
Lyric Pharmaceuticals*
Revolution Medicines*
City
Pleasanton
San Bruno
Berkeley
Hayward
Foster City
South San Francisco
Redwood City
Stage
Amount
Investors
Description
Early Stage
Foresite Capital Management, Morgan Stanley Alternative Investment Partners, Paladin Capital Management, $55,500,000 Venrock Genomics platform
Early Stage
Mohr Davidow Ventures, $17,982,000 Pappas Ventures
Early Stage
Technology-based Fidelity Biosciences, Mission solutions for cellular Bay Capital, Novartis Venture engineering and $11,550,000 Funds, undisclosed firms analysis
Early Stage
Precision molecular diagnostics technologies
$8,000,000 Bioveda China Fund
Therapeutics to address conditions of intellectual disability
Expansion
Mayo Medical Ventures, Sequoia Capital, undisclosed Biotechnology $20,499,900 firm company
Early Stage
Aperture Venture Partners, RiverVest Venture Partners, Sante Ventures, Third Point $20,400,000 Ventures
Clinical-stage pharmaceutical company
$45,000,000 Third Rock Ventures
Discovers and creates new therapies derived from natural products
Early Stage
Page 1 of 25